Advanced staged high-grade serous ovarian cancer (HGSOC) is the leading cause of gynecological cancer death in the developed world, with 5-year survival rates of only 25-30% due to late-stage diagnosis and the shortcomings of platinum-based therapies. A Phase I clinical trial of a combination of free cisplatin and poly(ADP-ribose) polymerase inhibitors (PARPis) showed therapeutic benefit for HGSOC. In this study, we address the challenge of resistance to platinum-based therapy by developing a targeted delivery approach. Novel electrostatic layer-by-layer (LbL) liposomal nanoparticles (NPs) with a terminal hyaluronic acid layer that facilitates CD44 receptor targeting are designed for selective targeting of HGSOC cells; the liposomes can be formulated to contain both cisplatin and the PARPi drug within the liposomal core and bilayer. The therapeutic effectiveness of LbL NP-encapsulated cisplatin and PARPi alone and in combination was compared with the corresponding free drugs in luciferase and CD44-expressing OVCAR8 orthotopic xenografts in female nude mice.
| INTRODUCTION
Epithelial ovarian cancer (EOC) is the second most common gynecological cancer and the leading cause of death from gynecologic malignancies in the developed world.
1,2 High-grade serous ovarian cancer (HGSOC) accounts for more than 70-80% of ovarian cancerassociated mortalities. 2, 3 This high mortality rate is attributable to an aggressive phenotype, diagnosis at advanced stages, and the development of resistance against mainstay platinum-based therapies. 4 Cisplatin and other platinum-based chemotherapies efficiently bind and induce DNA double-strand breaks (DSBs) and apoptosis in cancer cells 5 and are the current cytotoxic drugs of choice for ovarian cancer and other carcinomas. 6, 7 However, the rapid development of resistance often limits the effectiveness of platinum-based drugs alone against solid tumors such as HGSOC. 8, 9 Among solid tumors, 15-46% of HGSOC, 40-66% of triplenegative breast cancer, and 2-9% of non-small cell lung carcinoma are estimated to carry mutations in the p53, BRCA1, BRCA2, and PTEN genes, which are required for DNA damage repair via homologous recombination (HR). 5 Consequently, using DNA-damaging agents in combination with inhibitors of DNA damage repair proteins is a very attractive strategy. In the past 5 years, new classes of inhibitors have emerged against poly(ADP-ribose) polymerases (PARPs), a family of nuclear DNA damage repair enzymes with a role in the maintenance of genomic stability. 10 PARPs perform this function by initiating base excision repair and nucleotide excision repair of DNA single-strand breaks (SSBs). 11 The inhibition of SSB repair by PARP inhibitors (PARPis) induces and confers sensitivity and synthetic lethality to cells with defective HR-directed DSB repair. 11, 12 PARPis exhibit synergistic activity when combined with a DNA-damaging agent by interfering with DNA repair and potentiating the activity of the chemotherapeutic agent. The potentiation effect is achieved via inhibition of the catalytic activity of PARP by PARPis, or by trapping PARP at SSB sites, thereby stalling the replication fork and DNA transcription 10, 11 and eventually leading to apoptosis.
Different classes of PARPis of varying toxicity and efficacy have been developed. 13, 14 Of the five most clinically relevant PARPis, three of them: AZD2281 (olaparib, Lynparza; AstraZeneca, UK), 15 niraparib (Zejula, MK4827 Tesaro, Waltham, MA), 16 and rucaparib (Rubraca;
Clovis Oncology, Boulder, CO) 17 are FDA approved for the treatment of recurrent EOC. BMN 673 and veliparib are under investigation in different phases of clinical trials. 10, 11 The ability of DNA damaging agents to enhance apoptosis and reduce drug resistance in HR-deficient cells in tumors has led to a number of preclinical investigations. Rottenberg et al. 18 and Hay et al. 19 showed that the free-drug combination of AZD2281 with cisplatin or carboplatin significantly reduced resistance to platinum-based agents in BRCA1 mutated ovarian and breast cancer tumor-bearing mice and prolonged overall survival compared with either monotherapy. Others studies have shown high tolerance for AZD2281 alone but not in combination with other chemotherapies. 18 Several
Phase I-III clinical trials have been conducted to evaluate AZD2281 in combination with cisplatin and other chemotherapies in advanced breast and ovarian cancers in patients with BRCA mutation. 20, 21 Overall, the data indicated that the high-dose combination of cisplatin with AZD2281 was not tolerable in most patients. However, a moderate dose of cisplatin (60 mg/m 2 ) and AZD2281 (50 mg/twice daily) was better tolerated in most patients. In addition, the AZD2281 and cisplatin combination prolonged progression-free survival in patients compared to monotherapy, with tolerable side effects. 20, 22 BMN 673 (talazoparib) remains one of the most promising PARP1/2 inhibitors, and we have also tested BMN 673 alongside AZD2281 as monotherapies or in combination with cisplatin. 23 Preclinical testing has
shown that BMN 673 exhibits superior PARP inhibition and antitumor activity in vitro [24] [25] [26] [27] and in vivo. 28 A number of completed Phase I and II clinical trials of BMN 673 have evaluated its tolerability, efficacy, pharmacokinetics, and safety in both ovarian and metastatic breast cancer 24, 29 and Phase III clinical trials are currently underway. 11 In Phase I
and II clinical trials, the combination of BMN 673 with carboplatin showed synergy and significant therapeutic effects. However, hematologic toxicity was pronounced, particularly in gBRCA patients. 29 The clinical benefit of BMN 673 was 56-86% in both breast and ovarian cancer patients, with higher efficacy for the combination with carboplatin. 29 Although combinations of PARPis with cisplatin are efficacious, these preclinical and clinical trials of AZD2281 and BMN 673 alone or in combination with chemotherapies have revealed a number of hurdles that remain to be overcome to harness their full antitumor potential in the clinical setting. First, PARPis are highly hydrophobic, with limited bioavailability and a relatively rapid plasma clearance rate.
Rothenberg et al. 18 described rapid plasma clearance of AZD2281 when delivered in free form in tumor-bearing mouse models. Second, cisplatin, which remains a key platinum agent for ovarian cancer therapy, is subject to the development of resistance in tumors and therefore is typically administered at a high dose in the clinic, leading to its well-known systemic toxicity. 25, 26 Third, the therapeutic combination of cisplatin and AZD2281 is poorly tolerated in patients due to the overlapping toxicities of the two drugs 27 ; hence, only reduced doses have been evaluated in clinical trials. Fourth, the infusion and oral routes of administration of cisplatin and PARPis, respectively, can reduce medication compliance, leading to a less effective therapeutic response in patients. Moreover, to obtain the highest therapeutic index, both cisplatin and PARPi should be codelivered at their highest doses and at an appropriate therapeutic ratio to tumors, which is difficult to achieve via conventional free drug delivery approaches. Finally, the two drugs have different biodistribution profiles when administered via different routes by traditional approach. These factors affect the time it takes each drug to reach the tumor and the drug concentration delivered and can significantly affect treatment outcomes.
Codelivery of these drug combinations via a nanocarrier approach could significantly reduce or eliminate these hurdles. 30, 31 Advances in nanotechnology and nanomedicine have provided new opportunities for synergistic combinations of therapeutic agents via single multicompartment nanoparticles (NPs). [32] [33] [34] [35] The three main goals of this study are to (a) address the unmet clinical need for an effective and safe platform for the delivery of combination therapies to ovarian cancer; (b) design safe, full-dose delivery of cisplatin, and
PARPis to overcome cisplatin drug resistance in ovarian cancer therapy; (c) evaluate potential systemic toxicity associated with this treatment platform. We describe a novel approach to provide safe therapeutic delivery of cisplatin and PARPis to tumors using the layerby-layer (LbL) polymeric liposomal NPs approach. These NPs achieve synergistic drug delivery while inherently addressing many of the challenges associated with the conventional delivery of cocktails of free drugs, such as lack of targeted mechanistic delivery, reduced drug blood circulation, and the use of dual routes. 32, 36, 37 The HAterminated outer layer of the LbL NPs enables CD44 receptor targeting on HGSOC tumors, while the pH-responsive poly( L -lysine) (PLL) layer facilitates tunable intracellular release of the therapeutic cargo in tumor cells. 36, 38 We report the novel packaging of cisplatin with AZD2281 or BMN 673 in LbL NPs for orthotopic HGSOC therapy. We also perform a head-to-head comparison of the therapeutic efficacy of both free and nano-encapsulated delivery of AZD2281 and BMN 673 in vivo as a single maintenance agent in orthotopic HGSOC tumor-bearing mice. In summary, we observed an overall increase in survival and improved treatment outcomes in mice treated with the LbLencapsulated drug combination compared with free drug combination therapy.
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2 | RESULTS
| LbL polymeric liposomal NPs exhibit controlled drug release and inhibit HR
We designed single modular NPs for the efficient encapsulation of cisplatin and PARPi for synergistic dual-drug delivery (Figure 1a ). Two PARPis were used: AZD2281 (olaparib), which is FDA approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer, 15 and BMN 673, which is currently in clinical trials for BRCA-deficient ovarian cancer patients. 28 Both AZD2281 and BMN 673 are very hydrophobic, with poor solubility of 0.1 mg/mL in water. 14 We successfully formulated liposomal NPs by self-assembly of the
and cholesterol in a mass ratio of 56:39:5. The PARPis were introduced with a drug/lipid ratio of 9.7% (w/w). The net encapsulation efficiency was 26% for AZD2281, corresponding to a drug/lipid ratio of 2.5%
(w/w), and 21% for BMN 673, corresponding to a drug/lipid ratio of 2.4% (w/w), as determined by high performance liquid chromatograph mass spectrometry (HPLC/MS). The free drugs were initially purified by filtration through a sterile 0.2-μm filter membrane, followed by TFF. Final liposome purification and concentration were performed using TFF. 41 To enhance the structural stability, cell-targeting capability, and dual-drug release mechanism of the NP platform, we employed an LbL polyelectrolyte deposition approach. 32, 36 Polycation PLL (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) was deposited on the negatively charged liposomes to provide stability and pH sensitivity, followed by deposition of the polyanion, hyaluronic acid (HA, 40 kDa), to form the terminal layer. HA is a ligand for the receptor CD44, which is highly over-expressed on most ovarian cancer cells, 42, 43 and hence functions as a targeting layer on the NPs (Figure 1a ). Cryo-transmission electron microscopy (TEM) (TEM; The dual-drug release kinetics of the LbL NPs were investigated at 37 C in 300 mM citrate buffer with PBS at pH 5.5 to mimic physiological conditions in the endosomal compartment and tumor microenvironment. 44 As expected, AZD2281 ( Figure 1f ) and BMN 673 (Figure 1g ), small hydrophobic molecules entrapped by the phospholipid bilayer of the liposomes, were released first, followed by cisplatin. We hypothe- (Figure 2a,b) , we elected to further study OVCAR8 and COV362, which carry due to promoter hyper methylation and BRCA1 muta- expression, whereas COV362 carry BRCA1 mutation. 47, 51 Overall, in both cell lines, the free drugs showed greater potency than the encapsulated drugs, most likely due to the faster delivery of the free drugs to cells; the encapsulated drugs require an initial step of CD44
receptor-mediated endocytosis of the LbL NPs as well as controlled release from the carrier. Finally, these findings are also consistent with the significant elevation of γH2AX(Ser139) expression compared to RAD51 in BRCA-mutated cell lines after exposure to DNA-damaging agents. 49, 52 In addition to their role in DNA repair, PARPs are also substrates for Caspase 3 cleavage to initiate apoptosis. During apoptosis, PARP proteins undergo proteolytic cleavage, which can be monitored by western blot. The main PARP protein cleavage site is Asp214/Gly215, and the two resulting protein fragments can be used as markers of cleaved Caspase 3-mediated apoptosis activation. 53 We therefore 
| Evaluation of the hematological toxicity of NPs versus free drug delivery in vivo
Overall, in vivo preclinical testing and clinical trials have shown that the significant treatment response of cisplatin and PARPI combination therapy is accompanied by intolerable overlapping systemic toxicity, which requires a significant reduction of the dosing of either cisplatin or PARPI or their combination. Here, we administered escalating doses of cisplatin, AZD2281, and BMN 673 as monotherapies or combination therapies. 61 Two different dose studies were performed.
In the first dose study, the mice received the selected dose of each drug or the combination for three consecutive days, followed by thrice-daily monitoring for 2 weeks. 61, 62 In the second dose study, the mice received only a single dose and were again monitored for a 2-week period. In both studies, 6-to 8-week-old healthy immunocompetent BALB/c female mice were dosed with cisplatin, AZD2281, or BMN 673 individually or in combination as free drugs or encapsulated in NPs using the dosages previously described with moderate adjustment. 28 The standard procedure used is to determine the core NP drug dosing based on the cisplatin concentration.
In the first high-dose study ( Figure S2a Ovarian cancer is thought to originate from mesenchymal stem cells of the ovaries 63 and fallopian tubes, 64 and the mesentery and its 
| Correlation of apoptotic markers and biochemical metabolites with treatment response
The treatment of tumor xenografts with PARPis and cisplatin resulted 
| LbL polymeric liposomal NP assembly
Liposomes were formulated at a mass ratio of 56:39:5 using 1,2-distearoyl- were used as received from the vendor. All solutions were sterile filtered with a 0.2-μM filter prior to use. The liposomes suspension was diluted to 1 mg/mL and added dropwise to 45 mL of 500 μM PLL with rapid stirring, followed by TFF purification. The concentrated PLLlayered liposomes were diluted to 1 mg/mL and added dropwise to a rapidly stirring 45-mL solution of HA (10 μM), followed by stirring for 30 min at 4 C. The HA-layered liposomes were recovered by TFF wash as described previously. 41 
| Physicochemical characterization
The hydrodynamic size and PDI were determined using DLS (Malvern ZS90 particle analyzer, λ = 633 nm, material/dispersant RI 1.590/1.330).
The zeta potential was determined using laser Doppler electrophoresis 
| Cell viability and immunofluorescence
Cells were cultured at 5,000 cells/well in a 96-well plate in triplicate for 24 hr, followed by treatment with varying doses of free or encapsulated drugs alone or in combination. Cell viability was determined at 96 hr using the CellTitre Glo assay (Promega) on a Tecan microplate reader.
Immunofluorescence was performed as previously described. 75 Briefly, to detect HR, COV362, OVCAR4, and OVCAR8 cells were plated at 
| Western blotting
Western blotting was performed using a standard protocol. 76 The following primary antibodies were used at a dilution of 1:1,000: BRCA1 
| Mouse xenograft studies
The number of mice required in each treatment group to achieve statistical significance was determined by a power calculation. 77 
| Statistical analysis
Cell analysis was based upon triplicate experiments, and the results are presented as the mean ± SEM of at least three independent experiments. Student's t test was used for comparisons between two groups, and one-way ANOVA was used for comparisons among three or more groups of in vitro and in vivo data. Differences between samples were considered statistically significant at p < .05. Two-way ANOVA was used to compare histoscore for foci after treatments.
Survival data were analyzed using the Kaplan-Meier method, and logrank statistics was used to analyze the survival distribution. All statistical analyses were performed using the GraphPad Prism6 software (GraphPad Prism 5.0, GraphPad Software, La Jolla, CA).
